Wexford Capital’s Prevail Therapeutics PRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-18,963
Closed -$437K – 408
2020
Q4
$437K Sell
18,963
-19,000
-50% -$241K 0.07% 133
2020
Q3
$386K Buy
+37,963
New +$509K 0.1% 96

Wexford Capital's PRVL Position: Q1 2021 in Review

Wexford Capital sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 18,963 shares — an estimated $437K sold.

Wexford Capital first reported a position in PRVL in Q3 2020 and held it in 2 quarters. The position peaked at $437K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Wexford Capital reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 18,963 Prevail Therapeutics shares in Q1 2021, an estimated $437K.
  • Wexford Capital first reported a position in Prevail Therapeutics in Q3 2020 and held it in 2 quarters.
  • Wexford Capital's Prevail Therapeutics position peaked at $437K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.